Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses
dc.contributor.author | Wolf, John E. | en_US |
dc.contributor.author | Taylor, Joseph Richard | en_US |
dc.contributor.author | Tschen, Eduardo | en_US |
dc.contributor.author | Kang, Sewan | en_US |
dc.date.accessioned | 2010-04-01T14:53:21Z | |
dc.date.available | 2010-04-01T14:53:21Z | |
dc.date.issued | 2001-11 | en_US |
dc.identifier.citation | Wolf, John E.; Taylor, Joseph Richard; Tschen, Eduardo; Kang, Sewan (2001). "Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses." International Journal of Dermatology 40(11): 709-713. <http://hdl.handle.net/2027.42/65343> | en_US |
dc.identifier.issn | 0011-9059 | en_US |
dc.identifier.issn | 1365-4632 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/65343 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11737438&dopt=citation | en_US |
dc.description.abstract | Actinic keratoses (AKs) are epidermal skin lesions with the potential to develop into invasive squamous cell carcinoma (SCC). Treatment at an early stage may prevent development of SCC. Current treatment options are highly destructive and associated with significant side-effects. Early studies with topical diclofenac were encouraging and led to its evaluation for the treatment of actininic keratosis. Previous studies have demonstrated that 3% diclofenac in 2.5% hyaluronan gel is effective and well tolerated in the treatment of AK. The present study was designed to further explore the therapeutic potential of this gel. Methods This randomized, double-blind, placebo-controlled trial involved outpatients with a diagnosis of five or more AK lesions contained in one to three 5 cm 2 blocks. Patients received either active treatment (3% diclofenac gel in 2.5% hyaluronan gel) or inactive gel vehicle (hyaluronan) as placebo (0.5 g b.i.d. in each 5 cm 2 treatment area for 90 days). Assessments included the Target Lesion Number Score (TLNS), Cumulative Lesion Number Score (CLNS), and Global Improvement Indices rated separately by both the investigator (IGII) and patient (PGII). Results Results obtained from 96 patients at follow up (30 days after end of treatment) indicated that a significantly higher proportion of patients who received active treatment had a TLNS 0 compared to the placebo group (50% vs. 20%; P < 0.001). There was also a significant difference between the two groups in CLNS, with 47% of patients in the active treatment group having a CLNS 0 compared with only 19% in the placebo group ( P < 0.001). The proportion of patients with an IGII score of 4 (completely improved) at follow-up was 47% in the active treatment group compared with only 19% in the placebo group ( P < 0.001); for PGII these values were 41% vs. 17%, P < 0.001. Both treatments were well tolerated, with most adverse events related to the skin. Conclusions Topical 3% diclofenac in 2.5% hyaluronan gel was effective and well tolerated for the treatment of AK. | en_US |
dc.format.extent | 86837 bytes | |
dc.format.extent | 3110 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Ltd | en_US |
dc.rights | International Society of Dermatology | en_US |
dc.title | Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Dermatology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | From the Department of Dermatology, Baylor College of Medicine, Houston, Miami VA Medical Center and Department of Dermatology, University of Miami, Miami, Academic Dermatology Associates, Albuquerque, and the Department of Dermatology, University of Michigan, Ann Arbor, USA | en_US |
dc.identifier.pmid | 11737438 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/65343/1/j.1365-4362.2001.01324.x.pdf | |
dc.identifier.doi | 10.1046/j.1365-4362.2001.01324.x | en_US |
dc.identifier.source | International Journal of Dermatology | en_US |
dc.identifier.citedreference | Salasche, SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000 ; 1, S4 S7. | en_US |
dc.identifier.citedreference | Feldman, SR, Fleischer, AB Jr, McConnell, C. Most common dermatologic problems identified by internists. Arch Intern Med 1998 ;, 1990 944E158, 726 730. | en_US |
dc.identifier.citedreference | Lober, BA & Lober, CW. Actinic keratosis is squamous cell carcinoma. South Med J 2000 ; 7, 650 655. | en_US |
dc.identifier.citedreference | Moy, RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000 ; 1, S8 S10. | en_US |
dc.identifier.citedreference | Schwartz, RA. The actinic keratosis; a perspective and update. Dermatol Surg 1997 ; 23, 1009 1019. | en_US |
dc.identifier.citedreference | Nelson, MA, Eiknspahr, JG, Alberts, DS et al. Analysis of p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett 1994 ; 85, 23 29. | en_US |
dc.identifier.citedreference | Cockerell, CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ( actinic keratosis '). J Am Acad Dermatol 2000 ; 42, S11 S17. | en_US |
dc.identifier.citedreference | Dobson, JM, DeSpain, J, Hewett, JE, Clark, DP. Malignant potential of actinic keratoses and the controversy over treatment: a patient-orientated perspective. Arch Dermatol 1991 ; 127, 1029 1031. | en_US |
dc.identifier.citedreference | Glogau, RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000 ; 1, S23 S24. | en_US |
dc.identifier.citedreference | Dinehart, SM. The treatment of actinic keratoses. J Am Acad Dermatol 2000 ; 42, S25 S28. | en_US |
dc.identifier.citedreference | Chiarello, SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol Surg 2000 ; 8, 728 732. | en_US |
dc.identifier.citedreference | Epstein, E. Does intermittent pulse ' topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation? J Am Acad Dermatol 1998 ; 1, 77 80. | en_US |
dc.identifier.citedreference | Rivers, JK & McLean, DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel fro the treatment of actininc keratoses. Arch Dermatol 1997 ; 133, 1239 1242. | en_US |
dc.identifier.citedreference | Colbert, S, O'Hanlon, DM, Galvin, S et al. The effect of rectal diclofenac on pruritus in patients receiving intrathecal morphine. Anaesthesia 1999 ; 54, 948 952. | en_US |
dc.identifier.citedreference | Cardoso, MM, Carvalho, JC, Amaro, AR et al. Small doses of intrathecal morphine combined with systemic diclofenac for postoperative pain after caesarean delivery. Anesth Analg 1988 ; 86, 538 541. | en_US |
dc.identifier.citedreference | Marnett, LJ. Generation of mutagens during arachidonic acid metabolism. Cancer Metastasis Rev 1994 ; 13, 303 308. | en_US |
dc.identifier.citedreference | Isaacs, JT. Role of programmed cell death in carcinogenesis. Environ Health Perspect 1993 ; 101, 27 33. | en_US |
dc.identifier.citedreference | Masferrer, JL, Leahy, KM, Koki, AT et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000 ; 60, 1306 1311. | en_US |
dc.identifier.citedreference | Subbaramaiah, K, Zakim, D, Weksler, BB, Dannenberg, AJ. Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med 1997 ; 216, 201 210. | en_US |
dc.identifier.citedreference | Yantos, VA, Conrad, N, Azbawski, E, Cockerell, CJ. Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses. Semin Cutan Med Surg 1999 ; 1, 3 14. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.